Trevi Therapeutics (TRVI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$17.8M

Net income growth (year over year)

−44.68%

Net margin

—

Return on equity

−19.66%

EPS (trailing twelve months)

−$0.35

Book value per share

$2.26

P/E (trailing twelve months)

—

Price to book

5.37

Debt to assets

2.73%

Payout ratio

—

Dividend yield

—

Company profile

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

• How do I buy stock in Trevi Therapeutics (TRVI)?

  TRVI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.